R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Others - Small molecules (21)

Modality Indication Targets Stage Company Project No. Detail
1 Identification of HDAC6 Inhibitor Lead Compounds for the Development of Renal Fibrosis Therapy
Small molecules Renal fibrosis HDAC6 Lead Sookmyung Women's University RS-2026-25502920
2 Phase 1 Clinical Trial IND Clearance for the Osteoarthritis Therapeutic PRT101 Through Preclinical Studies, Toxicity Evaluation, and CMC Establishment
Small molecules Osteoarthritis SOX9 Preclinical PROTEINA RS-2026-25501950
3 NUAK1-Targeting Candidate Generation through Optimization and Preclinical Advancement
Small molecules CKD NUAK1 Candidate Genome & Company RS-2025-25453255
4 Cdo-Targeted Small Molecule Lead Compound Identification for Duchenne Muscular Dystrophy (DMD) Therapy
Small molecules DMD CDO Lead AniMusCure Inc RS-2025-25451838
5 Development of novel small molecule for CKD treatment
Small molecules CKD **** Preclinical Yuhan / R&D Institute RS-2025-25451385
6 Development of the First-in-class Drug for Sarcopenia
Small molecules Sarcopenia mTORC2 Lead Aliad Biopharma Inc. RS-2025-02223270
7 Hit optimization and lead generation activating NMJ for the treatment of Sarcopenia
Small molecules Sarcopenia ****receptor Hit AVENTI Inc. RS-2025-02213042
8 Discovery of hit/lead compounds for sepsis treatment targeting ASM pathogenesis via immune and intestinal barrier permeability mechanisms
Small molecules Sepsis ASM Hit K-MEDI hub RS-2025-02213034
9 A Phase 2b Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Evaluate the Efficacy and Safety of Isuzinaxib in Subjects with Diabetic Kidney Disease (PROMISS-DKD)
Small molecules Diabetic nephropathy pan-NOX 저해제 (NOX1,2,3,4,5, DUOX1,2) Phase 2 Aptabio RS-2025-02073057
10 Development of a Kv7.4 selective activator for the treatment of sensorineural hearing loss (noise-induced, ototoxic, and hereditary)
Small molecules Sensorineural hearing loss (noise-induced, ototoxic, and hereditary) Kv7.4 Candidate iN Therapeutics RS-2024-00349857
11 Hit optimization and lead generation activating PROKR1 to prevent and treat sarcopenia
Small molecules Sarcopenia PROKR1 agonist Hit Seoul National University RS-2024-00336938
12 Development of new drug Vonifimod for the treatment of Alopecia Areata
Small molecules Alopecia areata S1PR1&4 Phase 2 NEXTGEN Bioscience RS-2024-00332313
13 Development of osteoarthritis drug with a novel mechanism of inflammasome blockade
Small molecules Osteoarthritis Caspase Preclinical Innovo Therapeutics, Inc. RS-2023-00282719
14 Development of BKCa Channel Agonism Based New Drug Lead Compounds for Overactive Bladder Symptom
Small molecules Bladder disease BKCa Lead GIST RS-2023-00258812
15 Clinical Trial Development of Small Molecule Inhibitor for Progeria Treatment: Progerinin
Small molecules Progeria syndromes Progerin PPI Phase 2 PRG S&Tech Inc. RS-2023-00258708
16 Development of EFL.1101, a topical anticholinergic agent, for the Treatment of Hyperhidrosis
Small molecules Hyperhidrosis Muscarinic M3 Preclinical eFlask RS-2023-00258121
17 A novel GFRA1 agonist, JW0061 development for androgenic alopecia treatment
Small molecules Androgenetic alopecia GFRA1 Preclinical JW Pharmaceutical RS-2023-00217372
18 Identification a lead small-molecule drug to treat osteoarthritis through a cartilage regeneration mechanism
Small molecules Osteoarthritis OSCAR Hit KaiPharm Co., Ltd. RS-2022-00167006
19 Development of multi-functioning lead compounds for lymphedema
Small molecules Lymphedema Nrf2 Lead RAPPELER HN22C0095
20 Development of lead compound for treatment of hearing loss caused by cisplatin
Small molecules Hearing loss DRAK1, ADCK4, CDC42BPA Hit Kyungpook National University HN21C0107
21 Development of KV7.4 specific activator for the treatment of genetic hearing loss(DFNA2)
Small molecules Genetic Hearing Loss KV7.4 Lead Yonsei University HN21C0163
BACK